# An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors

> **NCT07371663** · PHASE1,PHASE2 · RECRUITING · sponsor: **Beijing Tide Pharmaceutical Co., Ltd** · enrollment: 266 (estimated)

## Conditions studied

- Solid Cancers
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Gastric (Stomach) Cancer
- Endometrial Cancer
- Malignant Melanoma

## Interventions

- **DRUG:** TCC1727 tablet 90mg
- **DRUG:** TCC1727 tablet 120mg
- **DRUG:** TCC1727 tablet 160mg
- **COMBINATION_PRODUCT:** benmelstobart Injection

## Key facts

- **NCT ID:** NCT07371663
- **Lead sponsor:** Beijing Tide Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-03
- **Primary completion:** 2028-09-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 266 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07371663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07371663, "An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT07371663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*